Soleno Therapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements About Drug Safety

Legal Accountability Looms for Soleno Therapeutics Amid Class Action Lawsuit

A class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) intensifies, spotlighting significant allegations regarding the company’s management practices and the commercial viability of its main product, diazoxide choline extended-release tablets (DCCR). The lawsuit, which encompasses claims from shareholders who purchased Soleno stock from March 26, 2025, to November 4, 2025, asserts that the company made materially false and misleading statements about DCCR’s safety and efficacy. These declarations reportedly misled investors and significantly contributed to financial losses tied to the drug’s decline in perceived market potential, following revelations of unaddressed safety concerns, including fluid retention issues associated with the medication.

The timing of this legal challenge correlates with heightened scrutiny surrounding Soleno, especially after a critical report from Scorpion Capital that claimed the company’s launch metrics for DCCR were misleading and pointed to alarming safety records among pediatric users. The complaint alleges that Soleno executives downplayed these risks leading up to the Phase 3 clinical trial, creating a false narrative that ultimately crumbled once the truth about the drug’s safety profile came to light. As concerns mount over DCCR's commercial viability, these legal challenges serve to not only reclaim investor losses but also highlight the importance of transparency in clinical reporting, especially in the biopharmaceutical sector where public trust is crucial.

Enforcement of shareholder rights is at the forefront of this emerging issue, as legal firms like DJS Law Group and Schall Law Firm mobilize to assist affected investors in joining the burgeoning case. They assert that despite the ongoing litigation, affected parties must act promptly to secure their representation by the upcoming May 5, 2026 deadline. This unfolding saga emphasizes the critical nature of legal accountability within the biopharmaceutical industry and the pressing need for companies like Soleno to maintain transparency in their reporting practices.

In parallel developments, Hagens Berman, another national shareholder rights firm, is actively investigating potential violations of federal securities laws by Soleno. They are urging investors who suffered financial setbacks related to DCCR to report their experiences, further demonstrating the sector's responsiveness to investor concerns. As the lawsuit progresses, it emphasizes a pivotal moment not just for Soleno, but also for similar companies in the industry, reaffirming the necessity of ethical governance and sincere communication of risks involved with therapeutic products.